Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Nov 13, 2025
CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
Read more at globenewswire.com
